A new collaboration between Elligo Health Research and WHYZE Health aims to simplify clinical trials in Europe by allowing patients and contract research organizations to more easily share information.
Electronic medical records miner Elligo already provides digital options to increase access to clinical research as care through its eSolutions Research Accelerator and ClinEdge Research Practice Management programs. Irish company WHYZE Health promises to deliver an intuitive, easy-to-use tool that gives patients more control over their course of care.
The two companies will jointly form a European medical advisory committee and invite other players in the healthcare and clinical trial spaces to join, according to a May 4 announcement.
“The current landscape for clinical research relies on doctors to encourage patients to seek out clinical trials,” said Christian Burns, president of Elligo. “However, the WHYZE Health platform will empower patients to bring research options to their doctors as well, eliminating the siloed approach to patient care and the housing of patient records.”
The ultimate goal is to create a “fully connected digital ecosystem that allows the exchange of validated, structured and up-to-date health data,” the companies said.
“WHYZE and Elligo together seek to create innovative solutions that utilize industry standards and healthcare data to fundamentally improve regulated clinical research—traditional, hybrid and at-home studies—and accelerate research conclusions,” said Frances Abeton, CEO of WHYZE Health. “This is the next evolution of healthcare to enable all stakeholders to facilitate a patient-centric collaborative care and research approach.”
Patients will be able to use the platform to share their healthcare information with population health and healthcare organizations as well as access up-to-date information on the best available treatment options, centers and support networks.
In turn, CROs will be able to access patient consented data through a secured exchange for clinical trials.
The latest announcement follows a busy 2021 for Elligo, which saw the Austin, Texas-based company acquire Root Health in June and secure $135 million in funding in September.